Progress in understanding AML and developing therapies that treat this blood cancer is occurring at an astounding pace. In this radio show, Dr. James Blachly, an AML expert from the James Comprehensive Cancer Center at Ohio State University will share a comprehensive overview of the latest treatments for all stages of AML. Dr. Blachly will discuss combination therapies, new immunotherapies, new diagnostic technologies and new targeted treatments that are being used in the clinic today and in development in AML clinical trials. Dr. Blachly will simplify the significant work being performed all over the world by dedicated researchers who have the goal of finding a cure for all patients with AML.
Dr. Blachly's practice consists of treating patients with acute myeloid leukemia along with other leukemias such as hairy cell leukemia, CLL and ALL within the hematology and transplantation clinic at the Ohio State University James Comprehensive Cancer Center in Columbus, Ohio. His current research conducted within the Blachly Lab focuses on understanding the role genetics and genomics play in the development, progression and treatment of acute myeloid leukemia and chronic lymphocytic leukemia, and returning that information back to the clinic, informing the design of future clinical trials to improve patient care.
As a complement to his clinical and research roles, Dr. Blachly is also an Assistant Professor of Biomedical Informatics and Internal Medicine at Ohio State University.
Dr. Blachly currently serves as co-chair for the Alliance for Clinical Trials in Oncology and co-chair elect for the Alliance for Clinical Trials in Oncology Translational Informatics Committee. He holds memberships with the American Society of Clinical Oncology, American Society of Hematology and the Society of Hematologic Oncology.
He is currently participating in several AML clinical trials including a phase 1b study of venetoclax and dinaciclib (MK7965) in patients with relapsed/refractory AML, a phase 1b/2 study of pinometostat in combination with standard induction chemotherapy in newly diagnosed AML with MLL rearrangement and a phase 1/1b/2a, 3-part open-label multicenter study looking at the use of AZD5991 monotherapy and in combination with venetoclax in relapsed/refractory blood cancers.
You definitely don't want to miss this show! If you can't attend live, we encourage you to still register as the recording will be sent out to everyone who registers after the event.
Thanks to our episode sponsor, Amgen
about the author
Katie joined the HealthTree Foundation as the Community Director for AML in 2021. She is a registered dietitian who previously worked at the VA hospital in Dallas, Texas where she coached veterans with blood cancer on how to use nutrition to improve their treatment outcomes and minimize cancer-related side effects. Katie is passionate about health education and patient empowerment. In her spare time, she loves to experiment with new recipes in the kitchen, spend time running outdoors and travel to new places.